NCT06769126

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Recruiting now Phase 2 Last updated 30 March 2026

What this trial tests

Phase 2 trial testing Biospecimen Collection in Extensive Stage Lung Small Cell Carcinoma in 900 participants. Currently enrolling.

Timeline

6 November 2025

Primary endpoint
31 December 2028

31 December 2029

Quick facts

Lead sponsor	SWOG Cancer Research Network
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	900
Start date	6 November 2025
Primary completion	31 December 2028
Estimated completion	31 December 2029
Sites	148 locations across United States

Drugs / interventions tested

• Biospecimen Collection — full drug profile →
• Ceralasertib
• Computed Tomography
• Durvalumab — full drug profile →
• Etoposide
• Magnetic Resonance Imaging
• Monalizumab — full drug profile →
• Platinum Compound — full drug profile →
• Positron Emission Tomography
• Saruparib
• Thoracic Radiation Therapy

Conditions studied

• Extensive Stage Lung Small Cell Carcinoma — all drugs for Extensive Stage Lung Small Cell Carcinoma →
• Lung Small Cell Carcinoma, A Subtype — all drugs for Lung Small Cell Carcinoma, A Subtype →
• Lung Small Cell Carcinoma, I Subtype — all drugs for Lung Small Cell Carcinoma, I Subtype →
• Lung Small Cell Carcinoma, N Subtype — all drugs for Lung Small Cell Carcinoma, N Subtype →

Sponsor

SWOG Cancer Research Network

Who can join

18 and older, any sex, with Extensive Stage Lung Small Cell Carcinoma or Lung Small Cell Carcinoma, A Subtype. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer cells that may give doctors more information about what is driving cancer and how to treat it. Based on the biomarker test results, study doctors can determine the subtype of ES-SCLC that study treatments can target. This study also tests different types of maintenance treatment for ES-SCLC with drugs durvalumab, saruparib, ceralasertib or monalizumab. Maintenance treatment is given after initial treatment and is given to help keep the cancer under control and prevent it from getting worse. Immunotherapy with monoclonal antibodies, such as durvalumab and monalizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Saruparib is a PARP inhibitor. PARP is a protein that helps repair damaged deoxyribonucleic acid (DNA). Blocking PARP may prevent cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Ceralasertib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for tumor cell growth. Giving biomarker selected personalized maintenance treatment with durvalumab, saruparib, ceralasertib or monalizumab may work better in treating patients with ES-SCLC.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

1. DNA repair and the contribution to chemotherapy resistance.
   Nesic K, Parker P, Swisher EM, Krais JJ. · · 2025 · cited 16× · PMID 40420317 · DOI 10.1186/s13073-025-01488-8
2. Synthetic lethality in cancer therapy: Mechanisms, models and clinical translation for overcoming therapeutic resistance.
   Li J, Zhang L, Shang Y, Liu J, et al · · 2026 · cited 1× · PMID 41537447 · DOI 10.1002/ctm2.70586
3. Nonclassical MHC-I Molecules: Emerging Therapeutic Targets in Next-Generation Immunotherapy.
   He W, McMichael AJ. · · 2026 · PMID 42027260 · DOI 10.1002/mco2.70742
4. Multi-omics reveals key molecular and cellular features of advanced small cell lung cancers associated with distinct therapeutic opportunities.
   Nones K, Lakis V, Dalley AJ, Ryan K, et al · · 2026 · PMID 41845530 · DOI 10.1186/s13073-026-01624-y
5. Antitumor activity and structure-activity relationship of poly (ADP-ribose) polymerase (PARP)-based dual inhibitors.
   Yang C, Shang Y, Li X, Li J, et al · · 2026 · PMID 41395847 · DOI 10.1080/14756366.2025.2598478